15 research outputs found
第3章第3節 身近な水辺の今と未来を話し合う
Impact of the prior weight on the noise (standard deviation in the Hoffman phantom white matter activity measurement). (TIF 416 kb
Additional file 1: Figure S1. of Model selection criteria for dynamic brain PET studies
Typical whole brain gray matter TACs of all the six brain PET radiotracers. (TIFF 43Â kb
Additional file 1: of Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC
Supplementary data. Table S1. Parent fractions (%). Table S2. Whole blood SUV. Table S3. Tumor [11C]erlotinib V T and K1 values. Table S4. Tumor [15O]H2O flow values. Table S5. SUV and TBR values (unitless). (DOC 170 kb
Additional file 2: of Quantification of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in glioma
Patient information, TACs, AIFs. (XLSX 443Â kb
Additional file 1: of Quantification of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in glioma
Details MR sequences. Details blood sample measurements. Table S1. Patient details. Figure S1. Transaxial views of the tumours on 20–40 min standardised uptake value maps of [18F]FET. Figure S2. Scatter (A) and Bland-Altman plot (B) of volume of distribution, VT, calculated with the 1T2kVb model versus the 2T4kVb model. Shaded areas are 95% confidence intervals. Figure S3. Scatterplot of volume of distribution (VT) versus cerebral blood flow (CBF) (A). The same plot with each patient indicated separately, connecting low, medium and high VOIs with lines (B). CBF data was not available for patient 6. Figure S4. Scatterplot of K1 versus cerebral blood flow (CBF) (A). The same plot with each patient indicated separately, connecting low, medium and high VOIs with lines (B). CBF data was not available for patient 6. Figure S5. Scatterplot of extraction versus cerebral blood flow (CBF). Figure S6. Scatterplots of simplified reference tissue model estimates of binding potential (BPND) (A) and K1-ratio (R1) (B) against the cerebral blood flow ratio (CBF-ratio). Figure S7. Scatter plot of SUV20–40 versus the volume of distribution (VT) calculated with the 2T4kVb model. (PDF 237 kb
Additional file 2:Â Supplementary Data. of Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
Information on the quality control of the radiolabelled tracer. (DOCX 16Â kb
Additional file 5: Figure S3. of Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
Additional examples of focal tumour uptake of 89Zr-RG7356 at 96Â h p.i.. From left to right: low dose CT, attenuation-corrected PET and fused image. (a) Tumour lesion: left side of the skull (patient 8, 450Â mg cohort). (b) Tumour lesion: sacrum (patient 13, 675Â mg cohort). (TIFF 6335Â kb
Additional file 1: Table S1. of Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
Specific scoring criteria for CD44 expression in patient samples. (DOCX 14Â kb